US Pharma MarketingThe post FDA approves ArkBio’s ziresovir for Phase II trial in severe RSV appeared first on Clinical Trials Arena.
FDA approves ArkBio’s ziresovir for Phase II trial in severe RSV
ArkBio has received approval from the FDA to begin a Phase II clinical trial of its AK0529 for use in severely ill infants infected with RSV. The post FDA approves ArkBio’s ziresovir for Phase II trial in severe RSV appeared first on Clinical Trials Arena .
ArkBio has received approval from the FDA to begin a Phase II clinical trial of its AK0529 for use in severely ill infants infected with RSV.
Source: Clinical Trials Arena